Bimekizumab for pyoderma gangrenosum
Treatments studied
Part of Injuries & trauma, Skin clinical trials.
This study tests a medication called bimekizumab to see if it helps people with pyoderma gangrenosum, a painful skin condition that causes deep ulcers. If you qualify, you'll receive the treatment and be monitored for about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need at least one pyoderma gangrenosum ulcer between 4 and 225 square centimeters.
- You must be willing to have skin biopsies (two at the start and two at 24 weeks).
- You must be on a stable dose of prednisone (20 mg/day) for at least 2 weeks before starting, and follow a tapering plan.
- You must be able to travel to the study site for visits and have internet access for video appointments.
- You cannot have inflammatory bowel disease or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a cream called ruxolitinib to treat pyoderma gangrenosum, a painful skin condition that causes deep ulcers. The cream is applied directly to the ulcer and may help it heal without the side effects of pills or injections.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
This study tests an experimental drug called SHR-1139 to see if it can help heal skin ulcers caused by pyoderma gangrenosum. If you qualify, you would receive the study drug and be monitored for safety and effectiveness.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This trial tests a new medicine called Bimekizumab (Bimzelx) to see if it improves PRP, a rare skin condition that causes red, scaly patches. If you have moderate to severe PRP, this treatment might help clear your skin.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.